Clarivate Epidemiology’s coverage of glomerulonephritis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of glomerulonephritis and end-stage glomerulonephritis for each country, as well as annualized case counts projected to the national population.
Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s glomerulonephritis forecast will answer the following question:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of glomerulonephritis over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts the following glomerulonephritis patient populations:
Diagnosed incident cases.
Diagnosed prevalent cases.
Diagnosed incident cases of end-stage glomerulonephritis.
Diagnosed prevalent cases of end-stage glomerulonephritis.
Literature review (studies included in/excluded from the analyses of glomerulonephritis)
Diagnosed incident cases of glomerulonephritis
Diagnosed prevalent cases of glomerulonephritis
Diagnosed incident cases of end-stage glomerulonephritis
Diagnosed prevalent cases of end-stage glomerulonephritis
Risk / protective factors applied to disease forecast models
Reference materials
Bibliography
Glossary
Abbreviation table
Mariah Hamalainen
Mariah Hamalainen, M.P.H., Epidemiologist, Epidemiology. Prior to joining Clarivate, Ms. Hamalainen earned her master’s degree in public health epidemiology from Florida International University, where she also worked as a graduate research assistant on an HIV testing and counseling study. She also completed two federally funded public health internships on data analysis and epidemiology. Her areas of interest are infectious diseases and women’s health.
Jackie Liu
Jackie Liu, M.P.H., Ph.D., Manager, Epidemiology. She first joined Clarivate as a Medtech analyst and worked on forecasting the global vascular devices market. She received her Ph.D. in molecular genetics and her M.P.H. in epidemiology from the University of Toronto in Canada.
